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Background
LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes,
aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia,
while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell
lymphomas, where it predicts better clinical outcome. The implication of LMO2 in B-cell acute
lymphoblastic leukemia must still be explored.
Design and Methods
We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia
patient samples with cytogenetic data (144 of them also with survival and immunophenotyp-
ical data) and in normal hematopoietic and lymphoid cells. 
Results
B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on
immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells,
displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature sub-
types. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher
LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid kary-
otype. Clinically, high LMO2 expression correlated with better overall survival in adult patients
(5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constitut-
ed a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival
rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043). 
Conclusions
Our data indicate that LMO2 expression depends on the molecular features and the differenti-
ation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2
expression in adult patients with a normal karyotype, a group which lacks molecular prognos-
tic factors, could be of clinical relevance.
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Introduction
The Lim Domain Only 2 gene (LMO2, also termed
RBTN2 and TTG2) encodes a cystein-rich LIM domain-
containing transcription factor that is required for com-
plete hematopoiesis in mice.1 While LMO2 is expressed
at various levels in virtually every tissue in fetal and adult
life, its expression in hematopoietic cells is tightly regu-
lated and varies at different ontogeny stages of matura-
tion.2 LMO2 was originally identified through its
involvement in recurrent chromosomal translocations in
T-cell acute lymphoblastic leukemia (T-ALL). Indeed,
constitutive activation of LMO2 in T cells by juxtaposi-
tion with the T-cell receptor (TCR) gene loci through
t(11;14)(p13;q11) or t(7;11)(q35;p13), or by the cryptic
deletion del(11)(p12p13), is characteristic of T-ALL.3,4 In
normal T-cell development, LMO2 is expressed in imma-
ture CD4/CD8 double negative thymocytes, but its
expression is down-regulated during T-cell maturation
and is absent in mature T cells.5 Ectopic expression of
LMO2 in the T-cell lineage in transgenic mouse models
leads to clonal expansion of T cells, eventually generating
human-like T-ALL.6 Moreover, during gene therapy of
patients with X-linked severe combined immunodefi-
ciency (X-SCID), retroviral insertion in the proximity of
the LMO2 gene resulted in the overexpression of this
gene and development of T-ALL in 3 children.7 These
data demonstrate that LMO2 functions as an oncogene
in this leukemia.
In normal B-cell differentiation and maturation, LMO2
is expressed mainly at two stages: at early lymphopoiesis
within the bone marrow and in germinal centers (GC) of
secondary lymphoid organs. LMO2 expression is also
found in B-cell lymphomas derived from GC lympho-
cytes, including follicular, Burkitt’s and diffuse large B-
cell (DLBCL) lymphomas, as well as in lymphocyte-pre-
dominant Hodgkin’s lymphoma.2 Remarkably, LMO2
expression is an independent prognostic factor of sur-
vival in patients with DLBCL treated with anthracycline-
based chemotherapy with and without rituximab,8 as
well as in chronic myeloid leukemia9 and pancreatic can-
cer.10 While marked advances have been made in estab-
lishing the significance and function of LMO2 in T-ALL
and B-cell lymphomas, its role in B-cell acute lym-
phoblastic leukemia (B-ALL) has not been investigated. 
B-ALL comprises cytogenetically distinct subgroups
defined by specific recurrent chromosomal transloca-
tions or by the presence of hyperdiploid and hypodiploid
karyotypes. Clinically, the distinction between these
genetic subgroups is important for prognosis and selec-
tion of optimal therapeutic options. In addition to cyto-
genetic analysis, the study of the immunophenotype of
the blasts is also important in the diagnosis of B-ALL, and
the distinction between T-, mature B- and precursor B-
phenotypes affects therapeutic decision making.11
This report assesses LMO2 expression in a series of
patients with B-ALL. Our data suggest that, in contrast to
T-ALL, LMO2 expression reflects the developmental
stage in which the blasts are arrested rather than being
an oncogenic event in this disease. Furthermore, we
show that LMO2 expression correlates with survival of
B-ALL patients, being an independent prognostic factor
in the subgroup with normal karyotype, particularly
among patients over 15 years of age.
Design and Methods
Patients’ samples and cell lines
LMO2 expression was assessed in a cohort of 247 patients with
acute lymphoblastic leukemia (ALL) who were treated according
to the PETHEMA (Spanish Group for the Study and Therapy of
Haematological Malignancies) protocols at the Departments of
Haematology of the Clínica Universidad de Navarra (Pamplona),
Hospital Reina Sofía (Cordoba) and other national institutions
belonging to the PETHEMA group.12,13 Full clinical and laboratory
data were available for 39 T-ALL and 145 B-ALL patients (one of
them lacking survival data) with a median age of 11.5 years (range
0.5-87 years), including 100 children under 15 years of age (median
5.5 years, range 0.5-14) and 84 patients over 15 years of age (mean
age 34.5, range 15-87). Sample collection was approved by the
individual institutional review boards of  the participating institu-
tions and informed consent was obtained from all adult patients
and children’s parents or legal guardians. 
Cytogenetic and molecular analyses were performed for all
samples (Online Supplementary Design and Methods). We found 32
cases (15%) with TEL-AML1 (ETV6-RUNX1) gene rearrangement,
41 cases (20%) with BCR-ABL rearrangement, 16 cases (8%) with
rearrangements involving the MLL gene, 9 cases (4%) with hyper-
diploid karyotype (more than 50 chromosomes), 21 cases (10%)
with miscellaneous abnormalities and 89 cases (43%) with normal
karyotype. Detailed information on the number of cases with
cytogenetic, immunophenotypical and survival data available is
provided in the Online Supplementary Table S1 and Figure S1. The
clinical and immunophenotypical characteristics of the B-ALL
patient samples are shown in Table 1. Methods for the sorting of
the normal lymphocyte subpopulations are available in the Online
Supplementary Appendix and Table S2, along with the cell lines
included in this study.
Quantitative real time PCR (Q-RT-PCR)
All patient samples were taken at initial diagnosis and come
from bone marrow aspirates. Only samples with more than 80%
blasts were included in this study. Total RNA from patients’
mononuclear bone marrow cells was extracted with Ultraspec
RNA isolation system (Biotecx). RNA quantity and quality were
assessed by spectrophotometric measurements with NanoDrop®
ND-1000 Spectrophotometer. Reverse transcription and Q-PCR
were performed as previously described14 using specific TaqMan
probes and 10x LightCycler TaqMan Master (Roche Applied
Science). LMO2 expression was normalized to ABL expression as
recommended by the Europe Against Cancer group for leukemic
samples.15 This group reported that ABL expression remained con-
stant not only in normal blood/bone marrow samples but also in
leukemic samples with different genetic alterations, including
cases with BCR-ABL rearrangement. We confirmed that ABL
expression remained constant among our samples with different
genetic alterations and in the normal karyotype subgroup (P=
0.761) (Online Supplementary Figure S2). The following primers
were used for PCR: forward LMO2 primer 5’-GGCGGCGCCTC-
TACTACA-3’, reverse LMO2 primer 5’-CCAAAAAGCCTGA-
GATAGTCTCT-3’, TaqMan LMO2 probe 5’-CTGGGCCG-
GAAGCTCTGCC-3’. Forward ABL primer 5’-TGGAGATAA-
CACTCTAAGCATAACTAAAGGT-3’, reverse ABL primer 5’-
GATGTAGTTGCTTGGGACCCA-3’, TaqMan ABL probe 5’-
CCATTTTTGGTTTGGGCTTCACACCATT-3’. 
Total RNA from cell lines and normal lymphocyte subpopula-
tions was extracted using TRIzol reagent (Invitrogen). cDNA syn-
thesis was performed with M-MLV reverse transcriptase
(Invitrogen) and Q-PCR was performed in the 7300 Real Time
LMO2 expression in B-ALL
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PCR System with Universal PCR Master Mix (Applied
Biosystems). Hs 00277106_m1 (Applied Biosystems) was the
probe for LMO2 and Hs 99999906_m1 for PGK1, selected as ref-
erence gene due to its good performance in our experience with
lymphoid samples and cell lines.16 LMO2 expression was also
assessed using these probes in 54 B-ALL patients to compare them
with normal lymphocytes and cell lines. 
When using either ABL or PGK1 as housekeeping genes, LMO2
expression was calculated as a ratio between the amount of LMO2
referred to a standard curve of cDNA and the amount of the refer-
ence gene referred to a standard curve of the same cDNA.
Correlation between the LMO2 expression results obtained using
PGK1 or ABL as housekeeping genes was highly significant
(P=0.003, Spearman’s Rho= 0.393). 
Statistical analysis
The SPSS 15.0 software was used for statistical analyses.
Kaplan-Meier curves and the log rank test were used for univariate
survival analysis, for which LMO2 expression was categorized
using its mean expression among all B-ALL patients as threshold
value (2.29). Overall survival (OS) was defined as the time interval
between the date of diagnosis and the date of death or last follow
up. Event-free survival (EFS) was defined as the time interval from
the date of initial diagnosis to the date of disease progression,
death from any cause or last follow-up evaluation. The relevant
clinical variables of these patients were also tested for their possi-
ble correlation with survival by the log rank test (Table 2), and a
multivariate Cox’s regression assay was performed including all
variables with P< 0.05. The possible association between nominal
variables and categorical LMO2 expression was tested by
Pearson’s c2 test. LMO2 expression was used as a continuous vari-
able for the remaining comparisons. Representative values are
given as median and range. Due to the lack of fit to the normal dis-
tribution of LMO2 expression values, tested by Kolmogorov-
Smirnov and Shapiro-Wilk tests, non-parametric comparisons
were performed: Mann-Whitney U test for comparisons of two
groups or Kruskal-Wallis test for comparisons of more than two
groups. Holms-Bonferroni correction was applied in cases of mul-
tiple comparisons with the Mann-Whitney U test. Correlation
between continuous variables was assessed by Spearman’s corre-
lation test. Differences were considered significant when P< 0.05.
Results
LMO2 expression changes during B-cell lymphopoiesis
and at distinct differentiation stages
LMO2 expression was measured by Q-RT-PCR in differ-
ent normal hematopoietic and B-cell subpopulations repre-
senting distinct differentiation stages. LMO2 expression
was highest at the earliest stages of bone marrow
hematopoiesis, decreasing gradually from hematopoietic
stem cells (HSCs) to the pro-B cell stage: median 38.23
(range 35.16-41.30) in HSCs, 19.08 (11.72-26.44) in early B
cells, and 14.59 (8.04-21.14) in pro-B cells. After the pro-B
stage, a sharp approximately 8-fold decrease in LMO2
expression was observed: 1.71 (1.10-2.32) in pre-B cells and
1.90 (1.55-2.25) in immature B cells. In secondary lymphoid
organs, LMO2 expression was increased at the GC B-cell
stage [13.81 (13.29-19.54)] compared to naïve B cells [5.67
(5.06-7.78)] and memory B cells [3.26 (3.16-3.95)] (Figure 1). 
Comparison of LMO2 expression in B-ALL, T-ALL, DLBCL
and B-cell precursors 
Similar levels of LMO2 expression were observed in pri-
mary B-ALL samples [2.13 (0.21-20.04)] and B-ALL cell
lines [1.63 (0.21-17.54)] (P=0.986) as well as in the pre-B
cell precursor subpopulation [1.71 (1.10-2.32)] (P=0.566)
(Figure 1). Next, we compared LMO2 expression between
cell lines of different origins. LMO2 expression tended to
be lower in T-ALL [0.71 (0.00-3.11)] and GCB-DLBCL
[1.45 (0.03-4.41)] cell lines compared to B-ALL cell lines
but the difference did not reach statistical significance
(P=0.151 and P=0.080, respectively) (Figure 1). As expect-
ed, LMO2 expression in ABC-DLBCL cell lines [0.02 (0.00-
1.41)] was lower compared to B-ALL and GCB-DLBCL cell
lines (P=0.018 and P=0.035, respectively). 
Immunophenotypical and cytogenetic subgroups 
of B-ALL exhibit variable levels of LMO2 expression
LMO2 expression was significantly higher in B-ALL
patients than in T-ALL patients [1.66 (0.04-10.90) vs. 0.70
R. Malumbres et al.
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Table 1. Clinical parameters in B-ALL patients.
Characteristic Total High LMO2 Low LMO2 P value
expression expression
(N=73) (N=72)
Age (y) P= 0.101
Median 11 8 18
Range 0.5-76 0.5-73 1-76
Age group P= 0.081
Childhood (<15 y) 81 46 35
Adult (≥15 y) 64 27 37
Gender P= 0.564
Male 78 41 37
Female 67 32 35
Hyperleukocytosis P= 0.781
Present 38 20 18
Absent 104 52 52
Immunophenotype P= 0.001*
Pro-B 35 28 7
Common-CD10+ 94 40 54
Pre-B 12 4 8
Mature 4 1 3
BCR-ABL P= 0.001*
Present 22 4 18
Absent 123 69 54
TEL-AML1 P= 0.797
Present 25 12 13
Absent 120 61 59
Three patients lacked data on hyperleukocytosis. The P values correspond to Pearson’s
c2 test except for the parameter “Age” that was compared with the Mann-Whitney U
test. *Significant P values.
Table 2. Factors associated with prolonged overall survival of B-ALL
patients.
Variable                                           Log rank            Multivariate Cox’s
                                                         P value             regression P value
Categorical LMO2 expression               0.004*                              0.068
Age group                                                  <0.001*                           0.003*
BCR-ABL                                                    <0.001*                          <0.001*
TEL-AML1                                                    0.001*                              0.958
Hyperleukocytosis                                    0.025*                              0.340
Gender                                                         0.340                                N.A.
*Significant P values.
(0.04-10.00), P=0.010] (Figure 2A). Cytogenetic and molec-
ular data on the B-ALL cases allowed the distinction of six
specific genetic subgroups with hyperdiploidy, BCR-ABL
rearrangement, TEL-AML1 rearrangement, translocations
involving the MLL locus, normal karyotype and cases with
miscellaneous alterations. B-ALL cases with BCR-ABL
rearrangement or hyperdiploid karyotype showed the
lowest LMO2 expression values [0.84 (0.00-3.30) and 0.80
(0.10-7.80) respectively], while all the remaining cases,
including those with MLL translocations [1.92 (0.10-
10.90)] or TEL-AML1 rearrangement [1.91 (0.10-5.40)]
exhibited higher levels of LMO2 expression (P=0.001)
(Figure 2B). 
B-ALL patient samples were also subclassified in four dif-
ferent immunophenotypical subgroups (pro-B, common-
CD10+, pre-B and mature). Among these subgroups, pro-B
cell ALL showed the highest LMO2 expression [4.49 (0.90-
10.90)] while B-ALL with common-CD10+ immuno -
phenotype [1.96 (0.10-7.80)], pre-B cell ALL [1.42 (0.20-
5.70)] and mature B-ALL [1.10 (0.50-2.70)] had lower
expression (P<0.001) (Figure 2C). Notably, the difference
in LMO2 expression between the pro-B and pre-B
leukemia immunophenotypes resembled the decrease in
LMO2 expression observed upon transition of pro-B to
pre-B cells in normal bone marrow (Figure 1). 
LMO2 expression is associated with survival 
in patients with B-ALL
Previous studies demonstrated that increased LMO2
expression correlates with better survival in DLBCL, as
well as in chronic myeloid leukemia and pancreatic cancer.
Therefore, we examined the possible correlation between
LMO2 RNA expression and patient clinical outcome in
ALL. We divided the patients in two subgroups with high
or low levels of LMO2 expression using the mean LMO2
expression value of the whole cohort of B-ALL patients
(2.29) as cut-off value. The median overall survival (OS)
was not reached in any of the two subgroups. The OS rate
was significantly higher in B-ALL patients with high levels
of LMO2 expression compared to patients with low levels
of LMO2 expression: the 5-year cumulative survival rate
with 95% CI was 77.2%(66.8%-87.6%) vs. 56.1%(44.1%-
68.1%); P=0.004 (Figure 3A). To determine whether
LMO2 expression is an independent predictor for OS in B-
ALL, we initially examined whether other known clinical
and laboratory prognostic factors also correlated with OS
by log rank test. In univariate analysis, age under 15 years
at diagnosis (childhood B-ALL) and the presence of TEL-
AML1 gene rearrangement correlated with favorable prog-
nosis, whereas the presence of hyperleukocytosis (leuko-
cyte count > 50,000/mm3) or BCR-ABL gene fusion were
associated with shorter OS (Table 2). Analyses of the pos-
sible correlation of MLL gene rearrangements or hyper-
diploid karyotypes with survival in our cohort of patients
were not performed because of the small number of cases
in these subgroups, which precluded any robust statistical
conclusion. 
A multivariate Cox’s regression analysis including age
group, hyperleukocytosis, presence of BCR-ABL or TEL-
AML1 gene rearrangements and subgrouping based on
LMO2 expression was performed. Only age over 15 years
and the presence of BCR-ABL gene rearrangement were
independently associated with worse OS in B-ALL
(P=0.003 and P<0.001, respectively). In contrast, LMO2
expression was not independently correlated with OS,
suggesting its association with age and/or the presence of
BCR-ABL rearrangement. By using Pearson’s c2 test, a
highly significant association between the presence of
BCR-ABL rearrangement and low LMO2 expression was
found (P=0.001). As age group is one of the main prognos-
tic factors in our cohort of patients, and the treatment pro-
tocols are more aggressive and effective in the age group
under 15 years, we performed a separate study on the
association between LMO2 expression and survival for
each age group. We found that in adult B-ALL cases high
LMO2 expression is a predictor of better outcome (5-year
survival rate 64.8% (42.5-87.1%) vs. 25.8% (10.9-40.7%),
P=0.001) (Figure 3B), while in patients under 15 years of
age there is no difference in mortality between the
patients with high or low LMO2 expression (P=0.673),
probably due to the low number of events among patients
in this age group (5-year survival rate 84.8% (76.4-93.2%)
vs. 42.7% (28.8-56.6%) in adults). As far as event-free sur-
vival (EFS) is concerned, patients older than 15 years with
high LMO2 expression displayed better survival rates than
those with low LMO2 expression (5-year survival rate
76.9% (59.1-94.7%) vs. 35.2% (9.9-60.5%), P=0.009)
(Figure 3C).
LMO2 expression is an independent prognostic factor
among the B-ALL cases with normal karyotype
In our series, the subgroup with normal karyotype
included the highest number of cases. The presence of a
normal karyotype did not correlate with OS (P=0.101).
Remarkably, in this subgroup of patients high LMO2
expression was associated with better OS: the 5-year sur-
vival rate was 80.3% (66.4-94.2%) vs. 63.0% (46.1-79.9%)
(P=0.043) (Figure 3D). Moreover, when multivariate Cox’s
regression analysis was applied, testing the variables
LMO2 expression levels, age group and hyperleukocyto-
sis, LMO2 expression and age group remained independ-
LMO2 expression in B-ALL
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Figure 1. LMO2 expression during B-cell differentiation and in B-lym-
phoid malignancies. LMO2 expression was measured by Q-RT-PCR.
The bar inside the boxes represents the median value, the limits of
the box the interquartile range, the whiskers the range of expected
values and (*) are outlier values. B-ALL: B-cell acute lymphoblastic
leukemia, pat: patient samples, T-ALL: T-cell acute lymphoblastic
leukemia, ABC-DLBCL: activated B-cell like diffuse large B-cell lym-
phoma, GCB-DLBCL: germinal center B-cell like diffuse large B-cell
lymphoma, HSC: hematopoietic stem cell, E-B: early B cell, IMB:






































































ent prognostic factors (P=0.045 and P=0.007, respectively).
When we performed a log rank test separately in the
two age groups, we found that higher LMO2 expression
remained a predictor of better outcome only in the
patients over 15 years of age: 5-year survival rate 70.0%
(36.7-103.3%) vs. 34.3% (9.4-59.2%), P=0.008 (Figure 3E).
We did not find any statistical association of EFS with
LMO2 expression in the group of patients with normal
karyotype and over 15 years of age.
Discussion
The role of LMO2 as oncogene in T-ALL6 and, converse-
ly, as favorable prognostic factor in DLBCL,8 CML9 and
pancreatic cancer,10 led us to evaluate the practically unex-
plored role of LMO2 in B-ALL. We found that LMO2 is
expressed in this disease, as previously proposed.2,17 Most
B-ALL cases exhibited LMO2 expression levels similar to
those measured in non-transformed pre-B cells, and even
in the cases with the highest LMO2 expression these lev-
els did not exceed those found in non-transformed pro-B
cells. As bone marrow B-cell precursors (both pro-B and
pre-B cells) are immunophenotypically very similar to the
blasts of the majority of B-ALL cases, the range of LMO2
expression found in B-ALL probably reflects the stage at
which these blasts undergo differentiation arrest. In this
regard, measurement of the expression of LMO2 in a B-
ALL sample might help to assess the grade of differentia-
tion of the malignant cells. Furthermore, LMO2 expres-
sion was associated with different cytogenetic subtypes of
B-ALL, being particularly low in BCR-ABL and hyper-
diploid cases. Overall, LMO2 RNA expression levels in B-
ALL seem to reflect the molecular and phenotypical char-
acteristics of the leukemic cells.
Despite the clear oncogenic role of LMO2 in T-ALL, this
is probably not the case in B-ALL. No translocations of this
gene have been reported in this disease, and other genetic
alterations involving the LMO2 locus are extremely rare
among B-ALL cases. For instance, genome-wide analysis
of 192 B-ALL samples using SNP arrays detected a deletion
of 155 kb upstream of the LMO2 gene locus in only one
case, in contrast to the 8% of T-ALL cases that showed
this alteration.18 Furthermore, among 226 B-ALL cases ana-
lyzed in our institution by conventional cytogenetics, 154
presented chromosomal abnormalities, but none showed
alterations in 11p13 (MJ Calasanz, unpublished data, 2010).
Moreover, in 3 out of 10 X-SCID patients treated with
retrovirus-mediated gamma(c) gene transfer into autolo-
gous CD34+ bone marrow cells, integration of the retro-
virus vector in the LMO2 gene promoter induced aberrant
LMO2 expression that led exclusively to T-ALL.19
Interestingly, while mature T cells repress LMO2 expres-
sion after their differentiation in the thymus,5 B cells great-
ly induce LMO2 expression during the immune response
in the GC reaction, reaching levels similar to that of pro-B
cells (Figure 1). This observation may suggest that elevated
LMO2 expression in B cells is not necessarily an oncogenic
event per se. Thus, all these data suggest that in contrast to
T-ALL, LMO2 does not act as an oncogene in B-ALL cells.
On the other hand, a recent report has described that in B-
ALL cells with t(17;19) (found in only 1% of B-ALL
patients20) the resulting fusion protein E2A/HLF induces
the transcription of LMO2, and upon LMO2 silencing
with shRNA the apoptotic rate increases by almost 10%.21
Nevertheless, this effect on apoptosis is modest and it is
possible that the oncogenic potential of E2A/HLF depends
on other transcription targets. Furthermore, mice trans-
genic for E2A/HLF fusion protein develop lymphoid
R. Malumbres et al.
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Figure 2. LMO2 expression changes between B-ALL and T-ALL and
among the main immunophenotypical and cytogenetic subtypes of
B-ALL. LMO2 expression was measured by Q-RT-PCR. (A) B-ALL vs. T-
ALL comparison was performed by the Mann Whitney U test. LMO2
expression among the different (B) cytogenetic and (C) immunophe-
notypical subgroups of B-ALL was compared by the Kruskal-Wallis
test. The corresponding P values are shown within the graphs. B-
ALL= B-cell acute lymphoblastic leukemia, T-ALL= T-cell acute lym-
phoblastic leukemia, Hyper= hyperdiploid karyotype (> 50 chromo-
somes), Normal: normal karyotype, MLL: translocations involving the
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malignancies with T-cell phenotype, and only very rarely
with B-cell precursor phenotype.22,23
Remarkably, we have found that high LMO2 expression
correlates with longer overall survival (OS) in patients
with B-ALL, in agreement with reports in DLBCL, CML
and pancreatic cancer. Part of this prognostic association in
our cohort of B-ALL patients may be attributed to the low
levels of LMO2 expression found in the subgroup of cases
with BCR-ABL rearrangement, a well-known adverse
prognostic factor.24,25 Interestingly, multivariate regression
analysis identified high LMO2 expression as an independ-
ent favorable prognostic factor for OS in patients with nor-
mal karyotype, particularly in patients over 15 years of
age, for which treatment protocols are not as intense and
effective as those used in younger patients. Because this
heterogeneous subgroup lacks known cytogenetic or
molecular markers that may predict survival, evaluation of
LMO2 expression in these patients may provide valuable
additional information in terms of risk stratification and
therapeutic tailoring. 
In terms of event-free survival (EFS), high LMO2 expres-
sion correlated with better outcome in B-ALL patients
LMO2 expression in B-ALL
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Figure 3. LMO2 expression predicts overall survival in patients with
B-ALL. B-ALL patient samples were analyzed for LMO2 expression by
Q-RT-PCR. LMO2 expression was categorized using its mean expres-
sion value (2.29) as the cut-off value. Overall survival (OS) was com-
pared between patients with high or low LMO2 expression (A) in the
whole cohort, (B) in patients older than 15 years, (D) in the subgroup
with normal karyotype, and (E) in patients older than 15 years and
with normal karyotype. (C) Event-free survival (EFS) was compared
between patients older than 15 years with high or low LMO2 expres-
sion. The patients remaining in the study (patients at risk) for each
subgroup at each time point and the probability associated with the
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over 15 years of age, agreeing with its usefulness as prog-
nostic factor in this subgroup. We could not find any asso-
ciation between LMO2 expression and EFS in the sub-
group of patients over 15 years of age and with normal
karyotype, probably due to the low number of relapses in
this subgroup (event-free survival data was only available
in 5 of the 28 patients in this subgroup).
It was recently reported that LMO2 protein expression
assessed by immunohistochemistry in 22 cases of B-ALL
did not predict survival in that patient cohort.17 The low
number of B-ALL cases enrolled in this study, as well as
the lack of stratification by immunophenotypical or cyto-
genetic characteristics of the blasts are probably the rea-
sons why this study failed to find statistical correlation
between LMO2 expression and survival in B-ALL. 
In summary, B-ALL cases express variable levels of
LMO2 that are associated with the immunophenotypical
and molecular features of this disease and correlate with
OS in our cohort of patients. Measurement of LMO2
expression should be of particular interest in B-ALL adult
cases with normal karyotype, in which high LMO2
expression is an independent favorable prognostic factor
for OS that could have clinical and therapeutic relevance.
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